Education
About Us
Working with TipRanks
Follow Us
UpHealth (UPHL)
OTHER OTC:UPHL
Top Page
UpHealth
(OTC:UPHL)
45Neutral
UpHealth (UPHL) vs. S&P 500 (SPY)
Market Cap
$3.79K
Dividend YieldN/A
Average Volume (3M)149.63K
Price to Earnings (P/E)―
Beta (1Y)-92.77
Revenue Growth-46.75%
EPS Growth70.83%
CountryUS
Employees374
SectorHealthcare
Sector Strength78
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-4.19
Shares Outstanding18,932,192
10 Day Avg. Volume29,054
30 Day Avg. Volume149,633
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
UpHealth Business Overview & Revenue Model
Company DescriptionUpHealth (UPHL) is a technology-driven healthcare company that operates across multiple sectors, including digital health, integrated care management, and telehealth services. The company's core products and services focus on enhancing patient care through innovative digital solutions and providing comprehensive healthcare delivery platforms for providers and patients.
How the Company Makes MoneyUpHealth makes money through a diversified revenue model that includes subscription fees for its digital health platforms, service fees for telehealth consultations, and licensing fees for its integrated care management solutions. The company also partners with healthcare providers and organizations to offer customized services, contributing to its revenue streams. Key factors contributing to UpHealth's earnings include its ability to integrate with existing healthcare systems and the growing demand for telehealth and digital health services.
UpHealth Financial Statement Overview
Summary
UpHealth's financial performance is mixed. While the company has experienced revenue growth, it struggles with profitability and cash flow issues. Negative net income, high leverage, and liquidity challenges pose significant risks despite efforts to reduce liabilities.Income Statement
UpHealth has shown significant revenue growth from 2019 to 2023, but profitability remains a challenge. The company has consistently reported negative net income, with a net loss of $57.84 million in 2023. Despite a positive gross profit margin of 48.55% in 2023, net profit margins are deeply negative, indicating high operational costs and inefficiencies.45
Neutral
Balance Sheet
The company's balance sheet reveals a high debt-to-equity ratio of 2.72, indicating significant leverage. Stockholders’ equity has decreased over the years, reflecting financial strain. However, the company has managed to reduce its total liabilities from the previous year, which is a positive sign. The equity ratio stands at 23.77%, suggesting a moderate reliance on debt financing.50
Neutral
Cash Flow
Cash flows are a concern, with negative operating and free cash flows reported in 2023. The operating cash flow to net income ratio is negative, highlighting the company's struggle to convert sales into cash. Free cash flow has improved slightly from 2022 to 2023, but remains negative, indicating ongoing liquidity challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 87.85M | 130.00M | 158.80M | 123.80M | 5.40M | 0.00 | Gross Profit |
| 41.88M | 63.14M | 54.02M | 30.54M | 3.89M | 0.00 | EBIT |
| -3.67M | 4.86M | -25.04M | -44.84M | -1.93M | -953.44K | EBITDA |
| -20.73M | -16.90M | -183.99M | -305.61M | -1.60M | -953.44K | Net Income Common Stockholders |
| -77.44M | -57.84M | -223.00M | -341.02M | -2.19M | 360.45K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 170.34M | 2.55M | 15.56M | 76.80M | 2.37M | 1.58M | Total Assets |
| 269.73M | 231.81M | 339.80M | 569.31M | 262.39M | 175.77M | Total Debt |
| 149.91M | 150.05M | 160.46M | 121.50M | 23.30M | 0.00 | Net Debt |
| 148.95M | 147.50M | 144.90M | 44.70M | 20.93M | -1.58M | Total Liabilities |
| 187.95M | 176.70M | 233.67M | 235.46M | 41.67M | 339.96K | Stockholders Equity |
| 81.78M | 55.10M | 105.15M | 318.46M | 220.72M | 175.43M |
| Cash Flow | Free Cash Flow | ||||
| -22.83M | -21.64M | -29.28M | -66.54M | -1.14M | -1.48M | Operating Cash Flow |
| -20.20M | -17.67M | -22.44M | -62.82M | -1.14M | -1.48M | Investing Cash Flow |
| 191.60M | 15.26M | -15.59M | 743.00K | 3.51M | -172.12M | Financing Cash Flow |
| -14.39M | -10.60M | -22.75M | 135.87M | 0.00 | 175.18M |
UpHealth Risk Analysis
UpHealth disclosed 57 risk factors in its most recent earnings report. UpHealth reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
UpHealth Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $10.24B | 54.48 | 21.24% | ― | 17.47% | 49.87% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
45 Neutral | $3.79K | ― | -104.96% | ― | -46.75% | 70.83% | |
45 Neutral | $1.31B | ― | -52.46% | ― | -1.26% | -338.56% | |
45 Neutral | $1.79B | ― | -14.75% | ― | -32.45% | 80.24% | |
43 Neutral | $106.30M | ― | -54.13% | ― | -1.81% | 70.88% |
* Healthcare Sector Average
Performance Comparison
UPHL
UpHealth
0.01
-0.94
-98.95%
TDOC
Teladoc
7.29
-7.20
-49.69%
AMWL
American Well
6.59
-7.81
-54.24%
CLOV
Clover Health Investments
3.33
2.60
356.16%
DOCS
Doximity
51.24
25.43
98.53%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.